glp 1 shortage The promise and peril of GLP-1 agonists: What we do (and don't) know as of August 2024 glp 1 shortage over Headlines

"The peak has come down a little bit," said Terence McManus, portfolio manager at Switzerlands Bellevue Asset Management and a Lilly shareholder, pointing to pricing in the new consumer market and the launch of generic versions of Novos Ozempic

Teva Pharmaceuticals Industries (NYSE: $TEVA) began marketing the authorized generic of Victoza this June, and Teva CEO Richard Francis told investors during the Q3 2024 earnings call that the company plans to launch generic Saxenda in 2025

No food works like Ozempic

Early reports of aspiration in fasting patients prompted changes to clinical guidance [4, 5]

Fortune 100 pharmaceutical and life sciences companies including Johnson & Johnson use Cypris to identify emerging IP threats, track competitor pipeline evolution, and discover partnership and acquisition targets before they surface in mainstream coverage